You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
|
|---|---|
| Published in |
Frontiers in Pharmacology, March 2016
|
| DOI | 10.3389/fphar.2016.00088 |
| Pubmed ID | |
| Authors |
Lieven D. Declercq, Rik Vandenberghe, Koen Van Laere, Alfons Verbruggen, Guy Bormans |
| Abstract |
Clinical trials aiming to develop disease-altering drugs for Alzheimer's disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion-and outcome criteria, due to a limited amount of objective biomarkers, is one of the major concerns. Non-invasive molecular imaging techniques, positron emission tomography and single photon emission (computed) tomography (PET and SPE(C)T), allow visualization and quantification of a wide variety of (patho)physiological processes and allow early (differential) diagnosis in many disorders. PET and SPECT have the ability to provide biomarkers that permit spatial assessment of pathophysiological molecular changes and therefore objectively evaluate and follow up therapeutic response, especially in the brain. A number of specific PET/SPECT biomarkers used in support of emerging clinical therapies in AD are discussed in this review. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 71 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 18% |
| Researcher | 11 | 15% |
| Student > Master | 10 | 14% |
| Student > Bachelor | 10 | 14% |
| Professor > Associate Professor | 4 | 6% |
| Other | 9 | 13% |
| Unknown | 15 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 19% |
| Chemistry | 11 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Neuroscience | 7 | 10% |
| Computer Science | 4 | 6% |
| Other | 12 | 17% |
| Unknown | 17 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2016.
All research outputs
#3,205,227
of 22,858,915 outputs
Outputs from Frontiers in Pharmacology
#1,390
of 16,130 outputs
Outputs of similar age
#54,537
of 301,001 outputs
Outputs of similar age from Frontiers in Pharmacology
#14
of 94 outputs
Altmetric has tracked 22,858,915 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,130 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 301,001 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.